Market Place
Sourcing Support
Pimicotinib Shows Improved Outcomes in Ph 3 Trial for Tenosynovial Tumor
11 Nov 2024 //
PR NEWSWIRE
Abbisko Presents Updated Irpagratinib Data for HCC at ESMO 2024
18 Sep 2024 //
PR NEWSWIRE
Abbisko Announces that FDA Has Granted Fast Track Designation for Pimicotinib
13 Dec 2023 //
PR NEWSWIRE
Merck KGaA, Darmstadt, Germany Strengthens Oncology Portfolio
04 Dec 2023 //
BUSINESSWIRE
Abbisko presented two updates of Pimicotinib at the 2023 CTOS Annual Meeting
06 Nov 2023 //
PR NEWSWIRE
Abbisko presented two preclinical research results at EORTC-NCI-AACR
16 Oct 2023 //
PR NEWSWIRE
Abbisko will debut two blockbuster clinical research results at ESMO
16 Oct 2023 //
PR NEWSWIRE
Abbisko reports updated results from TGCT Phase Ib study
30 May 2023 //
CLINICAL TRIALS ARENA
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib
27 May 2023 //
PR NEWSWIRE
Abbisko presents the research results of 5 programs at the 2023 AACR Meeting
16 Apr 2023 //
PR NEWSWIRE
Shanghai`s Abbisko out-licenses EGFR candidate in potentially nine-figure deal
02 Mar 2023 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.